ABSTRACT
No disponible
Subject(s)
Humans , Surgical Wound Infection/epidemiology , Surgical Wound Infection/prevention & control , Colon/surgery , Surgical Wound Infection/economics , Antibiotic ProphylaxisABSTRACT
The need for an access to the venous system, in order to infuse chemotherapeutic treatments or parenteral nutrition, has increased the number of central venous access systems (CVAS) implanted in the past years. Between February 1985 and December 1990, 87 devices were implanted in 76 patients (from 11 months to 15 years of age), with a median function time of 349 days (range: 7 to 1887 days). The overall incidence of complications was 0.10 per 10 days of catheterization, with complication rates for infection and thrombosis of 0.02 and 0.03, respectively. Nineteen systems were removed because of complications and 11 because of completion of the treatment. Of the cases, 97.7% included a follow-up period. The present study confirms the advantages of these devices, with a long working life and a low complication rate, being a good alternative for chronically ill children requiring long-term and/or cyclic intravenous therapy.
Subject(s)
Catheterization, Central Venous/methods , Infusions, Intravenous/instrumentation , Injections, Intravenous/instrumentation , Parenteral Nutrition/methods , Adolescent , Catheterization, Central Venous/instrumentation , Catheters, Indwelling , Chemotherapy, Adjuvant/methods , Child , Child, Preschool , Female , Humans , Infant , Infusion Pumps, Implantable , Infusions, Intravenous/methods , Injections, Intravenous/methods , Male , Neoplasms/therapy , Parenteral Nutrition/instrumentation , Treatment OutcomeABSTRACT
The role of eicosanoids in the development of immune response may be important to the viability of the implanted organ, given their complicated interaction with lymphokines and monokines which regulate the response. Due to this reason, more experiments in vivo are necessary to provide a better understanding of the behaviour of these compounds. This would help to clearly determine the role of these substances in the immune response--more exactly, in the allogenic transplant rejection--creating new ways for its control.
Subject(s)
Eicosanoids/immunology , Graft Rejection/immunology , Leukotrienes/immunology , Transplantation Immunology/immunology , Antigen-Antibody Reactions/immunology , Humans , Immunity, Cellular/immunology , Transplantation, HomologousABSTRACT
A review of the current state of carcinoid tumors is presented, with special attention to the diagnostic, pronostic and new therapeutic aspects. In spite of being a well known entity the diagnosis is difficult being confirmed only by pathologic findings. The current medical therapy and surgical options are described. New surgical alternatives--organ cluster transplantation--seems to be the definitive solution in metastatic disease.
